FAQ

HIV Protease Inhibitors [MoA]

Known as: HIV Protease Inhibitors, Human Immunodeficiency Virus Protease Inhibitors 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2015
024619962015

Related topics

Related topics

23 relations
AmprenavirAtazanavirAtazanavir sulfateErgotamine
(More)

Related mentions per year

Related mentions per year

1937-2018
1960198020002020
HIV Protease Inhibitors [MoA]
Ritonavir
lopinavir
Methysergide
Amprenavir
Indinavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Sp1 transcription factor interaction with accumulated prelamin a impairs adipose lineage differentiation in human mesenchymal stem cells: essential role of sp1 in the integrity of lipid vesicles.
Lamin A (LMNA)-linked lipodystrophies may be either genetic (associated with LMNA mutations) or acquired (associated with the use… (More)
Is this relevant?
2009
2009
Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
A major concern regarding the chronic administration of antiretroviral drugs is the potential for induction of drug efflux… (More)
Is this relevant?
2007
2007
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV; -15% to +37… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2006
2006
HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.
Glioblastomas are malignant brain tumors that are rarely curable, even with aggressive therapy (surgery, chemotherapy, and… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum… (More)
Is this relevant?
2004
2004
Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.
BACKGROUND Although recommended as initial therapy for patients with dyslipidemia who are taking human immunodeficiency virus… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
BACKGROUND Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2000
2000
In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
BACKGROUND Pharmacologic treatment of emotional disorders in HIV-infected patients can be more easily optimized by understanding… (More)
Is this relevant?
2000
2000
Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.
Polymorphonuclear leukocytes (PMNL) from human immunodeficiency virus (HIV)-infected patients exhibit accelerated apoptosis and… (More)
  • figure 1
  • table 1
Is this relevant?
1998
1998
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
OBJECTIVE To assess the pharmacokinetic interaction between ritonavir and saquinavir. METHODS Ritonavir and saquinavir were… (More)
Is this relevant?